BACKGROUND: Transcatheter aortic valve implantation (TAVI) is safe and effective for patients with aortic stenosis (AS) who have a high operative risk. However, there is still debate on the effect of TAVI in AS patients with reduced left ventricular ejection fraction (REF). The objective of the review is to clarify the efficacy of TAVI and the impact of REF on the 30-day and midterm mortality in these patients. METHODS: Studies on TAVI were searched in PubMed, Embase, and the Cochrane Library databases and were included in this review following predefined criteria. Data were extracted and pooled risk ratios (RR) were synthesized to explore the relationship between REF and 30-day plus midterm mortality. RESULTS: Twenty-eight studies comprising 14,099 patients were included in the analysis of the association of REF with the prognosis of patients after TAVI. An average increase in left ventricular ejection fraction of 8-10 % was observed among these patients after TAVI. REF was not related to the 30-day mortality [RR = 1.90, 95 % confidence interval (CI) = 0.80-4.47]; however, it was related to the midterm mortality (RR = 1.49, 95 %CI = 1.14-1.93) of patients undergoing TAVI. Patients with low-flow and low-gradient AS had a higher 30-day mortality (RR = 1.54, 95 %CI = 1.11-2.13) and midterm mortality rate (RR = 1.69, 95 %CI = 1.33-2.14) compared with AS patients without these characteristics. The mortality of TAVI patients was significantly lower than that of those undergoing conservative therapy, and was similar to that of patients undergoing surgical aortic valve replacement. CONCLUSION: REF was not associated with 30-day mortality, but it was associated with the midterm mortality of TAVI patients. Patients with REF could benefit from TAVI compared with conservative therapy.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is safe and effective for patients with aortic stenosis (AS) who have a high operative risk. However, there is still debate on the effect of TAVI in AS patients with reduced left ventricular ejection fraction (REF). The objective of the review is to clarify the efficacy of TAVI and the impact of REF on the 30-day and midterm mortality in these patients. METHODS: Studies on TAVI were searched in PubMed, Embase, and the Cochrane Library databases and were included in this review following predefined criteria. Data were extracted and pooled risk ratios (RR) were synthesized to explore the relationship between REF and 30-day plus midterm mortality. RESULTS: Twenty-eight studies comprising 14,099 patients were included in the analysis of the association of REF with the prognosis of patients after TAVI. An average increase in left ventricular ejection fraction of 8-10 % was observed among these patients after TAVI. REF was not related to the 30-day mortality [RR = 1.90, 95 % confidence interval (CI) = 0.80-4.47]; however, it was related to the midterm mortality (RR = 1.49, 95 %CI = 1.14-1.93) of patients undergoing TAVI. Patients with low-flow and low-gradient AS had a higher 30-day mortality (RR = 1.54, 95 %CI = 1.11-2.13) and midterm mortality rate (RR = 1.69, 95 %CI = 1.33-2.14) compared with AS patients without these characteristics. The mortality of TAVI patients was significantly lower than that of those undergoing conservative therapy, and was similar to that of patients undergoing surgical aortic valve replacement. CONCLUSION: REF was not associated with 30-day mortality, but it was associated with the midterm mortality of TAVI patients. Patients with REF could benefit from TAVI compared with conservative therapy.
Authors: Neil E Moat; Peter Ludman; Mark A de Belder; Ben Bridgewater; Andrew D Cunningham; Christopher P Young; Martyn Thomas; Jan Kovac; Tom Spyt; Philip A MacCarthy; Olaf Wendler; David Hildick-Smith; Simon W Davies; Uday Trivedi; Daniel J Blackman; Richard D Levy; Stephen J D Brecker; Andreas Baumbach; Tim Daniel; Huon Gray; Michael J Mullen Journal: J Am Coll Cardiol Date: 2011-10-20 Impact factor: 24.094
Authors: Peter Wenaweser; Thomas Pilgrim; Nadja Roth; Alexander Kadner; Stefan Stortecky; Bindu Kalesan; Fabienne Meuli; Lutz Büllesfeld; Ahmed A Khattab; Christoph Huber; Balthasar Eberle; Gabor Erdös; Bernhard Meier; Peter Jüni; Thierry Carrel; Stephan Windecker Journal: Am Heart J Date: 2011-05-11 Impact factor: 4.749
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Sammy Elmariah; Igor F Palacios; Thomas McAndrew; Irene Hueter; Ignacio Inglessis; Joshua N Baker; Susheel Kodali; Martin B Leon; Lars Svensson; Philippe Pibarot; Pamela S Douglas; William F Fearon; Ajay J Kirtane; Hersh S Maniar; Jonathan J Passeri Journal: Circ Cardiovasc Interv Date: 2013-11-12 Impact factor: 6.546
Authors: Ulrich Fischer-Rasokat; Matthias Renker; Christoph Liebetrau; Maren Weferling; Andreas Rolf; Mirko Doss; Helge Möllmann; Thomas Walther; Christian W Hamm; Won-Keun Kim Journal: PLoS One Date: 2019-11-26 Impact factor: 3.240